A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Clinical trial NCT03467373 · COMPLETED
Trial details
- NCT number
- NCT03467373
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-13
- Primary completion
- 2024-12-02
- Enrollment
- 111
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.